kp-1199
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 12, 2019 (NCT03880487)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
- Cyclooxygenase-1INHIBITOR
PTGS1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03880487 | Phase 1 | Mar 12, 2019 | Department of Defense, Kalyra Pharmaceuticals, Inc., Pharmaceutical Research Associates, Inc. (PRA) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2019 |
| Kalyra Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2019 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1